Tags

Type your tag names separated by a space and hit enter

Is triple negative a prognostic factor in breast cancer?
Breast Cancer. 2008; 15(4):303-8.BC

Abstract

BACKGROUND

Breast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer.

PATIENTS AND METHODS

Between January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically.

RESULTS

Patient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence.

CONCLUSION

TN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed.

Authors+Show Affiliations

Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto 862-8505, Japan. j_nishimura2002@yahoo.co.jpNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18369692

Citation

Nishimura, Reiki, and Nobuyuki Arima. "Is Triple Negative a Prognostic Factor in Breast Cancer?" Breast Cancer (Tokyo, Japan), vol. 15, no. 4, 2008, pp. 303-8.
Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008;15(4):303-8.
Nishimura, R., & Arima, N. (2008). Is triple negative a prognostic factor in breast cancer? Breast Cancer (Tokyo, Japan), 15(4), 303-8. https://doi.org/10.1007/s12282-008-0042-3
Nishimura R, Arima N. Is Triple Negative a Prognostic Factor in Breast Cancer. Breast Cancer. 2008;15(4):303-8. PubMed PMID: 18369692.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is triple negative a prognostic factor in breast cancer? AU - Nishimura,Reiki, AU - Arima,Nobuyuki, Y1 - 2008/03/29/ PY - 2007/07/23/received PY - 2008/01/08/accepted PY - 2008/3/29/pubmed PY - 2009/2/4/medline PY - 2008/3/29/entrez SP - 303 EP - 8 JF - Breast cancer (Tokyo, Japan) JO - Breast Cancer VL - 15 IS - 4 N2 - BACKGROUND: Breast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer. PATIENTS AND METHODS: Between January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically. RESULTS: Patient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence. CONCLUSION: TN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed. SN - 1880-4233 UR - https://www.unboundmedicine.com/medline/citation/18369692/Is_triple_negative_a_prognostic_factor_in_breast_cancer L2 - https://dx.doi.org/10.1007/s12282-008-0042-3 DB - PRIME DP - Unbound Medicine ER -